Tim is prescribed the small molecule inhibitor bortezomib to treat multiple myeloma. Based on the “-zomib” suffix of the drug’s name, bortezomib is most likely a:

Question

Tim is prescribed the small molecule inhibitor bortezomib to treat multiple myeloma. Based on the “-zomib” suffix of the drug’s name, bortezomib is most likely a:

BlackTom AI · Accepted Answer

The question asks us to interpret the meaning of the suffix "-zomib" in the context of a drug name used to treat multiple myeloma.
Option a) PARP inhibitor: PARP inhibitors are a class of drugs that target poly (ADP-ribose) polymerase enzymes and are often used in cancers with BRCA mutations. They are typically named with suffixes like "-parib" (e.g., olaparib, niraparib), not "-zomib". This option mislabels the common naming convention for PARP inhibitors, making it unlikely based on the suffix clue.
Option b) Tyrosine kinase inhibitor: Tyrosine kinase inhibitors (TKIs) include drugs such as imatinib or erlotinib. Their names frequently end in "-nib" rather than "-zomib". While both endings end in "-ib" sounds, the specific "-zomib" pattern is not associated with TKIs, so this choice conflicts with the naming convention suggested by the question.
Option c) CDK inhibitor: CDK inhibitors, used in various cancers, are commonly named with endings like "-nib" as well (e.g., palbociclib). They are not typically recognized by the suffix "-zomib". This makes this option unlikely when considering the suffix cue provided.
Option d) Proteasome inhibitor: Drugs with the suffix "-zomib" are well known to include proteasome inhibitors used in multiple myeloma, such as bortezomib and carfilzomib. The characteristic naming pattern here aligns with proteasome inhibition and with the clinical context of multiple myeloma, which strengthens this option as the correct association with the suffix clue.
In terms of reasoning about the underlying pharmacology, proteasome inhibitors disrupt the proteasome-mediated degradation of intracellular proteins, leading to accumulation of misfolded or regulatory proteins and inducing apoptosis in myeloma cells. The other classes listed — PARP inhibitors, TKIs, and CDK inhibitors — have distinct targets and are typically identified by different naming conventions, and their mechanisms do not align with the specific suffix clue provided in the question.
Putting the pieces together, the suffix clue points toward a proteasome-targeting agent, while the other options mismatch both the naming convention and the intended pharmacological category. This alignment between the suffix and the drug class in option d explains why this option is the best fit given the stem and context.

Tim is prescribed the small molecule inhibitor bortezomib to treat multiple myeloma. Based on the “-zomib” suffix of the drug’s name, bortezomib is most likely a:单项选择题

类似问题

You own a bond that pays $64 in interest annually. The face value is $1,000 and the current market price is $1,021.61. The bond matures in 11 years. What is the yield to maturity?

Which of the following statements is CORRECT?

It will cost $9,600 to acquire an ice cream cart that is expected to produce cash inflows of $3,600 a year for three years. After the three years, the cart is expected to be worthless. What is the payback period?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单